UTI Asset Management Company Ltd

- No explicit mention of any upcoming equity fundraising in the transcript. - New Fund Offers (NFOs) mentioned are primarily around passive funds: - UTI Nifty IT ETF - UTI Nifty 10 years benchmark G-Sec ETF - UTI 5 years benchmark G-Sec ETF - No active equity funds are planned for launch in the near term; focus is on passive products. - No direct mention of new debt fundraising; however, there is a shift in investment from mutual funds to G-Secs and bonds for better yields. - Seed investments in international funds remain around USD 18 million with plans to reduce but awaiting favorable market conditions. In summary, the immediate product pipeline is focused on passive equity and debt ETFs with no announced equity or debt capital raising at the corporate level.

- UTI AMC is expanding its international presence with new offices recently opened in Paris and planned in the USA, indicating capital investment in global expansion. - Legal expenses related to these international operations are expected in the second half of the financial year. - Major expenses, including hiring and establishment costs linked to the US operations, are anticipated in the first quarter of the next financial year (FY 2024-25). - Employee base is increasing, primarily on the distribution side, supporting expansion and sales efforts. - There are plans to reduce seed investments in international funds, currently around USD 18 million, but this will depend on growth in key flagship schemes and market conditions. - No specific details on other large-scale capex or strategic investments were provided.

- UTI Mutual Fund is focusing on international business growth, with new offices opened in Paris and upcoming in the USA, expecting volume growth from these markets. - Despite potential margin compression due to reduction in Total Expense Ratio (TER), overall AMC margins are expected to be protected through volume growth. - Growth of passive funds and ETFs may reduce management fees overall, but volume growth is anticipated to compensate. - Revenue is expected to improve on a year-on-year basis due to increased volumes. - Distribution expansion through opening of new offices (29 opened, 8-10 more planned) and increased sales team hiring aims to drive higher sales. - Focus on volume growth is a key strategy to offset pressure on margins and drive revenue growth. - Seed investments are planned to be reduced as sales in international funds improve, indicating potential revenue optimization in global operations.

- Operating margins (PAT margin) are expected to improve due to operating leverage as costs are not increasing substantially while volumes grow (Page 17). - The expense growth guidance is moderate, with overall expenses projected to increase by 4-5% year-on-year (Page 13). - Employee costs are expected to rise modestly, with a 2-3% increase on standalone basis and slightly higher costs due to international expansion (Paris and US offices) (Pages 8, 14). - Growth in AUM, particularly in international business and passive funds, is expected to drive volume growth and improve absolute yields, contributing positively to profits (Pages 17, 18). - Revised fee structures, especially the reduced management fees for EPFO mandates, may slightly compress yields but are offset by higher volumes (Pages 18, 19). - Overall, the company is confident of strong growth opportunity in the mutual fund industry aligned with improving market and regulatory momentum (Page 17).

The provided transcript from the UTI Mutual Fund earnings call does not disclose any specific information regarding current or expected order book or pending orders. The discussion primarily focuses on: - Management fees and expense ratios, including recent reductions. - Market share trends across equity, hybrid, and fixed income categories. - ETF and equity yield figures. - Distribution commission structures. - Expansion plans including opening offices internationally (Paris, USA). - Product pipeline focusing on ETFs (Nifty IT ETF, G-Sec ETFs). - No references were made to order books, pending orders, or order backlogs. Therefore, there is no information available in the transcript related to current or expected orderbook or pending orders.